Malabsorption

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

Retrieved on: 
Montag, Februar 13, 2023
Capsule, Stomach, Patent, Biotechnology, Enzyme replacement therapy, Hope, CF, Patient, Biologics license application, Cystic fibrosis, Safety, CNA, CP, Clinical trial, EPI, CFA, Research, Health, Letter, Food, Exocrine pancreatic insufficiency, Malabsorption, PERT, IP, BOCA, First wave, Quality of life, BLA, Gastrointestinal disease, Pharmaceutical industry

BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company’s clinical programs and recent events.

Key Points: 
  • BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company’s clinical programs and recent events.
  • First Wave BioPharma was not immune to this unfortunate trend, but we weathered the storm.
  • We look forward to capitalizing on several growth drivers in 2023 and reaching our next clinical milestone.
  • Phase 2 Adrulipase Trial Initiated, Topline Data Expected in Mid-2023
    Key to our value proposition is the advancement of our adrulipase program.

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

Retrieved on: 
Donnerstag, Februar 2, 2023
Safety, EPI, Patient, CF, First wave, Steatorrhea, Quality of life, Cystic fibrosis, Exocrine pancreatic insufficiency, SPAN, Malabsorption, CFA, Clinical trial, First, CNA, BOCA, Pharmaceutical industry

Patient dosing is expected to commence by mid-February with topline results from the study to be available by mid-2023.

Key Points: 
  • Patient dosing is expected to commence by mid-February with topline results from the study to be available by mid-2023.
  • “We are very pleased that patient screening has begun so soon after initiating the Phase 2 clinical trial,” said James Sapirstein, President and CEO of First Wave BioPharma.
  • “This urgency speaks to the collective focus of First Wave’s clinical development team, the investigators and trial sites, and our CRO partner to conduct a successful Phase 2 clinical trial.
  • “Exocrine pancreatic insufficiency is a debilitating condition that is challenging to manage for individuals with cystic fibrosis with currently available porcine-derived therapies,” said Dr. Steven Boas, founder of the Cystic Fibrosis Institute and Cystic Fibrosis Center of Chicago.

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

Retrieved on: 
Dienstag, Januar 31, 2023
Food, PERT, Safety, EPI, Patient, First wave, Stomach, IND, Cystic fibrosis, Exocrine pancreatic insufficiency, SPAN, CFA, Capsule, Malabsorption, Clinical trial, FDA, Gastrointestinal tract, CNA, Investigational New Drug, BOCA, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Enzyme replacement therapy, Pharmaceutical industry

The Phase 2 multi-center study is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.

Key Points: 
  • The Phase 2 multi-center study is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.
  • First Wave BioPharma expects to initiate patient screening in early February 2023, with topline data anticipated by mid-2023.
  • “We are very pleased to announce the initiation of the Phase 2 clinical trial investigating our new formulation of adrulipase as a potential treatment for EPI associated with cystic fibrosis and chronic pancreatitis,” said James Sapirstein, President and CEO of First Wave BioPharma.
  • The Phase 2 SPAN trial is designed to investigate the safety, tolerability and efficacy of a new enteric microgranule formulation of adrulipase.

Global Plant-based Beverages Market Report 2022 to 2028: Wide Range of Varieties and Choices for Customers Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Januar 10, 2023
Retail, Fitness & Nutrition, Health, Food, Beverage, Lactose intolerance, Meat, Drink, Meal, Cholesterol, Dairy, Malabsorption, Growth, Snack, Mineral, Soybean, Nutritional science, Taste, Plant, Food, Coffee

The Global Plant-based Beverages Market size is expected to reach $48.8 billion by 2028, rising at a market growth of 11.2% CAGR during the forecast period.

Key Points: 
  • The Global Plant-based Beverages Market size is expected to reach $48.8 billion by 2028, rising at a market growth of 11.2% CAGR during the forecast period.
  • Plant-based beverages are beverages that can be substituted for dairy products.
  • Soymilk, rice milk, coconut milk, and almond milk are some of the most popular plant-based beverages.
  • Although most media coverage of plant-based diets focuses on meat substitutes, dairy alternatives as well as plant-based beverages should not be neglected.

California Protons Celebrates 5th Anniversary with the Treatment of its 4,000th Patient

Retrieved on: 
Mittwoch, Dezember 21, 2022
Holiday, Proton therapy, Museum, Patient, Sarcoma, Vomiting, Neoplasm, Radiation, Travel, SAN, Liver, Head, Lymphoma, Heart, Marketing, American Cancer Society, Neck, Extrapyramidal system, Colonoscopy, Hotel del Coronado, Breast, Cancer, MD, Multimedia, Fatigue, Spine, Nausea, Diarrhea, Dehydration, City, Heartburn, Malabsorption, Prostate, Physician, Incidence, Lung, Medical imaging, Proton

SAN DIEGO, Dec. 21, 2022 /PRNewswire/ -- California Protons Cancer Therapy Center celebrated its 5th Anniversary with the treatment of its 4,000th patient with proton therapy. Proton therapy is a form of radiation treatment that is less invasive than traditional x-ray radiation. Protons stop at the tumor site and do not travel past it, resulting in less radiation dose to surrounding healthy tissues and organs, and a decrease in side effects and risks of secondary cancers. Primarily used for cancer treatment, in some cases proton therapy can also be used to treat non-cancerous tumors.

Key Points: 
  • SAN DIEGO, Dec. 21, 2022 /PRNewswire/ -- California Protons Cancer Therapy Center celebrated its 5th Anniversary with the treatment of its 4,000th patient with proton therapy.
  • Because of this, people travel from all over California and neighboring states to access proton therapy treatment."
  • Sandi finished her final treatment and rang the bell as the center's 4,000th patient on December 7 – which also was the 5th Anniversary of California Protons.
  • California Protons Cancer Therapy Center is one of only two proton therapy centers in California and 40 nationwide.

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

Retrieved on: 
Donnerstag, Dezember 15, 2022
Roche, Synthetic biology, Associate, Intellectual property, TID, HCU, Genetic engineering, Clinical trial, Inflammatory bowel disease, Kidney, PKU, Absorption, Urine, FDA, Uric acid, AES, Webcast, Safety, Roux-en-Y anastomosis, Diet, Homocystinuria, Pain, Gout, Phenylketonuria, Malabsorption, MD, Risk, Șaeș, University of Alabama at Birmingham School of Medicine, Associate professor, ID, History, IBD, University, Metabolism, Patient, Therapy, Probiotic, Pharmaceutical industry, Urology, AbbVie

CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB8802 has demonstrated proof of concept through clinically significant lowering of urinary oxalate in a Phase 1b study in patients with a history of gastric bypass surgery.

Key Points: 

    EvoEndo Announces Ambulatory Payment Classification (APC) Reassignments for Flexible Transnasal Esophagogastroduodenoscopy (EGD)

    Retrieved on: 
    Donnerstag, Dezember 15, 2022
    General Health, Health, Medical Devices, Gastroesophageal reflux disease, Pediatric gastroenterology, Nutrition, CMS, Degenerative disease, Centers for Medicare & Medicaid Services, Italian ship Leonardo (A 5301), VR, Learning, Patient, Biopsy, OPPS, APC, Endoscopy, Eosinophilic esophagitis, EOE, FDA, Malabsorption, EGD, CPT, Virtual reality, Center for Medicare and Medicaid Innovation, Italian ship Ammiraglio Magnaghi (A 5303), Abdominal pain, Columbia University Irving Medical Center, Dysphagia, Physician, TNE, Medicare

    We look forward to sharing this new payment alignment with healthcare providers as they consider the clinical and financial value of unsedated transnasal endoscopy, said Heather Underwood, Chief Executive Officer at EvoEndo.

    Key Points: 
    • We look forward to sharing this new payment alignment with healthcare providers as they consider the clinical and financial value of unsedated transnasal endoscopy, said Heather Underwood, Chief Executive Officer at EvoEndo.
    • Unsedated transnasal endoscopy with the EvoEndo Single-Use Endoscopy System is designed to reduce preparation and recovery time for upper endoscopy procedures and to eliminate potential risks associated with sedation.
    • The EvoEndo System includes a sterile, single-use, flexible gastroscope designed for unsedated transnasal upper endoscopy, and a small portable video controller.
    • The EvoEndo Comfort Kit includes virtual reality (VR) goggles for patient distraction during the unsedated transnasal endoscopy procedure.

    HealthWell Foundation Opens Vitamins and Supplements Fund to Assist Individuals Living with Alagille Syndrome

    Retrieved on: 
    Mittwoch, November 30, 2022
    Growth, Severe cognitive impairment, Heart, Skin, Itch, Cholestasis, Safety, Vitamin, Genetic disorder, Life, Insurance, Alagille syndrome, Patient, Rickets, Education, Nutrient, Skeleton, Coagulopathy, Charitable organization, Bile, Failure, Quality of life, Jaundice, Malabsorption, Liver, Health insurance, Dietary supplement, Operation

    GERMANTOWN, Md., Nov. 30, 2022 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is proud to announce that it has launched a new fund to provide financial assistance to patients living with Alagille Syndrome. Through the new fund, HealthWell will provide up to $1,500 in financial assistance to eligible patients within the United States and U.S. territories who have annual household incomes up to 500 percent of the federal poverty level to obtain vitamins and supplements for the management of their condition.

    Key Points: 
    • Alagille syndrome (ALGS) is a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys.
    • Because the body cannot properly absorb fats and fat-soluble vitamins (vitamins A, D, E, and K), affected children may also experience growth deficiencies and failure to thrive.
    • Vitamins and supplements are a critical component in managing the condition but are often costly and represent a financial hardship for many families," commented Roberta Smith, President, Alagille Syndrome Alliance.
    • To determine eligibility and apply for financial assistance, visit HealthWell's Alagille Syndrome Vitamins and Supplements Fund page.

    AbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship "Thriving Student Awards"

    Retrieved on: 
    Mittwoch, September 14, 2022
    Neuroscience, Ontario Graduate Scholarship, NORTH, CF, Health, Fibrosis, Twitter, Virology, Central Time, Graduate school, Conditional sentence, ID, Mucus, Creativity, LinkedIn, Population, Malnutrition, Cystic Fibrosis Foundation, Pancreas, Patient, Human, Gastroenterology, Instagram, Student, Goal, Human resource management, Cystic fibrosis, Lists of schools in England, Medicine, AbbVie, Education, Malabsorption, Forestry, Management, Facebook

    Following this voting period, scholarships totaling $25,000 each will be awarded to two commendable students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system.

    Key Points: 
    • Following this voting period, scholarships totaling $25,000 each will be awarded to two commendable students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system.
    • "Beyond being a recipient of the AbbVie CF Scholarship, I am grateful I was able to share my cystic fibrosis story with the world," said Melissa W., 2021 Thriving Graduate Student.
    • Earlierthis year, AbbVie selected 40 undergraduate and graduate students living with CF as recipients of a $3,000 scholarship for use during the 2022-2023 academic year.
    • More information about the AbbVie CF Scholarship criteria and application can be found at www.AbbVieCFScholarship.com .

    Accord Healthcare Releases Generic Drug Proven Effective Against Vitamin B12 Deficiency

    Retrieved on: 
    Donnerstag, Mai 19, 2022
    Urination, Dementia, DNA, Vitamin B12 deficiency, Infertility, Intas Biopharmaceuticals, Confusion, Patient, Food and Drug Administration, Solution, Quality of life, Folate, NIH, Research, Accord, FDA, Cobalt, Central nervous system, Safety, Technology, Palpitations, Product, Heart, Vitamin B12, Skin, National, Dietary supplement, GI, Diarrhea, Weight loss, Fatigue, Cyanocobalamin, Malabsorption, Pharmaceutical industry

    DURHAM, N.C., May 19, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Cyanocobalamin Injection to its injectable drug portfolio. Cyanocobalamin is used to treat vitamin B12 deficiencies due to malabsorption associated with pernicious anemia, folic acid deficiency, GI dysfunction, and multiple other conditions. This new product is offered as a solution in 1mL and is currently available to ship.

    Key Points: 
    • DURHAM, N.C., May 19, 2022 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Cyanocobalamin Injection to its injectable drug portfolio.
    • Cyanocobalamin is used to treat vitamin B12 deficiencies due to malabsorption associated with pernicious anemia, folic acid deficiency, GI dysfunction, and multiple other conditions.
    • "This is a dynamic time for Accord Healthcare US, and we're proud to add Cyanocobalamin to our portfolio of injectables," said Accord CEO Jeff Hampton.
    • Because vitamin B12 contains the mineral cobalt, compounds with vitamin B12 activity are collectively called cobalamins .1 Sensitivity to cobalt and/or Vitamin B12 is a contraindication.